Summary
Mary Shean is a drug development and program management executive with over 20 years of experience leading global, cross-functional teams across protein therapeutics and small molecules, with deep expertise in oncology, rare diseases, and orphan drug strategies. As cofounder of Quality Forward and former senior leader at companies including Genentech, Amgen, Celgene, Lexicon, and Raptor/Horizon, she builds program and portfolio infrastructure—establishing PM functions, portfolio governance, risk management, and enterprise PM systems—to take programs from preclinical through post-marketing and launch readiness. She has a track record rescuing and accelerating Phase 3 programs, driving enrollment increases and ensuring NDA and launch preparedness, and she frequently serves as interim project lead during transitions. Comfortable in organizations of all sizes and across US and ROW markets, she pairs hands-on operational leadership with alliance and regulatory savvy. A Duke-trained scientist by background, she brings a rare combination of technical grounding and pragmatic process design that scales development capabilities quickly.
11 years of coding experience
4 years of employment as a software developer
Bachelor of Arts (B.A.) with Certificate in Genetics, Physical and Biological Anthropology, Anatomy, and Genetics, Bachelor of Arts (B.A.) with Certificate in Genetics, Physical and Biological Anthropology, Anatomy, and Genetics at Duke University